Infection, Human Immunodeficiency Virus Clinical Trial
Official title:
An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects
GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV versus sixteen 150mg capsules daily for APV. This study is designed to provide additional information on long term safety and tolerability of FPV containing regimens for those subjects who received FPV in previous GlaxoSmithKline studies.
Status | Completed |
Enrollment | 753 |
Est. completion date | October 2010 |
Est. primary completion date | October 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 13 Years and older |
Eligibility |
Inclusion Criteria: - Male or non-pregnant/non-lactating females >/=13 years of age (or >/= 18 years of age according to local requirements). - Received fosamprenavir through prior participation in APV20001, APV30002, APV30003 or PRO30017 or have participated in APV30001 or other studies as deemed appropriate by the project team. Exclusion Criteria: - Permanent discontinuation of GW433908 in a previous study due to intolerance. - An active CDC Class C Event. - Any condition which, in the opinion of the investigator, would preclude a subject from participation. |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Brazil | GSK Investigational Site | Campinas | São Paulo |
Chile | GSK Investigational Site | Santiago | Región Metro De Santiago |
France | GSK Investigational Site | Le Kremlin Bicêtre Cedex | |
France | GSK Investigational Site | Marseille | |
France | GSK Investigational Site | Paris Cedex 10 | |
France | GSK Investigational Site | Paris Cedex 20 | |
France | GSK Investigational Site | Vandoeuvre Les Nancy Cedex | |
France | GSK Investigational Site | Villejuif Cedex | |
Italy | GSK Investigational Site | Genova | Liguria |
Portugal | GSK Investigational Site | Coimbra | |
Spain | GSK Investigational Site | Badajoz | |
Spain | GSK Investigational Site | Barcelona | |
United Kingdom | GSK Investigational Site | London | |
United Kingdom | GSK Investigational Site | London | |
United States | GSK Investigational Site | Denver | Colorado |
United States | GSK Investigational Site | Fort Lauderdale | Florida |
United States | GSK Investigational Site | Fountain Valley | California |
United States | GSK Investigational Site | Galveston | Texas |
United States | GSK Investigational Site | Manhasset | New York |
United States | GSK Investigational Site | Orlando | Florida |
United States | GSK Investigational Site | Orlando | Florida |
United States | GSK Investigational Site | San Francisco | California |
United States | GSK Investigational Site | Sarasota | Florida |
United States | GSK Investigational Site | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
ViiV Healthcare | GlaxoSmithKline |
United States, Brazil, Chile, France, Italy, Portugal, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Any Adverse Event (AE): Interim Analysis | An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the "Other (Non-Serious) Adverse Events" section. | Baseline (Day 1) up to 31 January 2006 (up to Week 264) | No |
Primary | Number of Participants With Any Adverse Event (AE): Final Analysis | An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A list of all adverse events is reported in the "Other (Non-Serious) Adverse Events" section. | Post January 2006; for up to 241 weeks | No |
Primary | Change From Baseline in the Indicated Clinical Chemistry Parameters at Weeks 48, 96, 120, 132, 168, 180, 204, and 216 | Fasting blood samples of participants were collected for the assessment of triglycerides (Tri.), cholesterol (Chol.), high density cholesterol (HDL), low density cholesterol (LDL), and fasting blood glucose (FBG). Change from Baseline at Weeks (W) 48, 96, 120, 132, 168, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1). | Baseline (Day 1) and Weeks 48, 96, 120, 132, 168, 180, 204, and 216 | No |
Primary | Median Values of the Indicated Clinical Chemistry Parameters at Weeks 120, 180, 204, 216, and 432 | Fasting blood samples of participants were collected for the assessment of triglycerides, cholesterol, high density cholesterol (HDL), low density cholesterol (LDL), and fasting blood glucose (FBG). | Weeks 120, 180, 204, 216, and 432 | No |
Primary | Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 120, 180, 204, and 216 | blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1). | Baseline (Day 1) and Weeks 48, 120, 180, 204, and 216 | No |
Primary | Change From Baseline in the Total Cholesterol/HDL Ratio at Weeks 48, 96, 132, and 168 | Fasting blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. Change from Baseline at Weeks 48, 96, 132, and 168 was calculated as the value at that particular week minus the value at Baseline (Day 1). | Baseline (Day 1) and Weeks 48, 96, 132, and 168 | No |
Primary | Median Value of the Total Cholesterol/HDL Ratio at Weeks 120, 180, 204, 216, and 432 | Fasting blood samples of participants were collected for the assessment of the total cholesterol/HDL ratio. The ratio of total cholesterol/HDL was calculated by dividing the value of total cholesterol by the value of HDL. | Weeks 120, 180, 204, 216, and 432 | No |
Primary | Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 120, 180, 204, and 216 | Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. Change from Baseline at Weeks 48, 120, 180, 204, and 216 was calculated as the value at that particular week minus the value at Baseline (Day 1). | Baseline (Day 1) and Weeks 48, 120, 180, 204, and 216 | No |
Primary | Change From Baseline in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase at Weeks 48, 96, 132, and 168 | Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. Change from Baseline at Weeks 48, 96, 132, and 168 was calculated as the value at that particular week minus the value at Baseline (Day 1). | Baseline (Day 1) and Weeks 48, 96, 132, and 168 | No |
Primary | Median Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Serum Lipase Values at Weeks 120, 180, 204, 216, and 432 | Blood samples of participants were collected for the assessment of AST, ALT, and serum lipase. | Weeks 120, 180, 204, 216, and 432 | No |
Secondary | Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <400 and <50 Copies Per Milliliter at Baseline and Weeks 48, 120, 180, and 216 (MD=F and Observed) | Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point. Participants in the NFV populations had received antiretroviral therapy prior to Baseline. | Baseline and Weeks 48, 120, 180, and 216 | No |
Secondary | Percentage of Participants With Plasma HIV-1RNA <400 and <50 Copies Per Milliliter at Baseline and Weeks 12, 24, 48, 60, 96, and 132 (MD=F and Observed) | Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma, is an efficacy measure for antiretroviral drugs. In the MD=F analysis, participants who had missing data at or had discontinued the study prior to a certain time point are classified as non-responders. In the observed analysis (OA), data are presented for the number of participants still enrolled in the study at a certain time point. | Baseline and Weeks 12, 24, 48, 60, 96, and 132 | No |
Secondary | Percentage of Participants With Plasma HIV-1RNA <50 Copies Per Milliliter at Baseline and Weeks 120, 180, 240, 300, 360, 420, and 432 (Observed) | Blood samples of participants were collected for the assessment of HIV-1RNA copies in plasma. Viral load, measured in RNA copies per milliliter of plasma,is an efficacy measure for antiretroviral drugs. | Baseline and Weeks 120, 180, 240, 300, 360, 420, and 432 | No |
Secondary | Cluster of Differentiation Antigen 4 (CD4+) Cell Count at Baseline and Weeks 48, 120, 168, 180, 204, and 216: Observed Analysis | Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV. | Baseline and Weeks 48, 120, 168, 180, 204, and 216 | No |
Secondary | Cluster of Differentiation Antigen 4 (CD4+) Cell Count at Baseline and Weeks 24, 48, 96, 132, and 168: Observed Analysis | Blood samples of participants were collected for the assessment of CD4+ cell count. CD4+ cells are white blood cells that are important in fighting infection. HIV infects CD4+ cells, replicates in them, and destroys them. CD4+ cell count provides a measure of the status of the immune system and to what extent it is affected by HIV. | Baseline and Weeks 24, 48, 96, 132, and 168 | No |
Secondary | Median Plasma HIV-1 RNA at Baseline and Weeks 24, 48, 72, 96, 120, 144, 168, 180, 204, and 216 | Blood samples of participants were collected for the assessment of plasma HIV-1 RNA. | Baseline and Weeks 24, 48, 72, 96, 120, 144, 168, 180, 204, and 216 | No |
Secondary | Median Plasma HIV-1 RNA at Baseline and Weeks 12, 24, 48, 72, 96, 132, and 168 | Blood samples of participants were collected for the assessment of plasma HIV-1 RNA. | Baseline and Weeks 12, 24, 48, 72, 96, 132, and 168 | No |
Secondary | Median Plasma HIV-1 RNA at Weeks 180, 240, 300, 360, 420, and 432 | Blood samples of participants were collected for the assessment of plasma HIV-1 RNA. | Weeks 180, 240, 300, 360, 420, and 432 | No |
Secondary | Number of Participants With HIV-1 Disease Progression to CDC Class C, or New CDC Class C or Death, From Baseline | The number of participants with progression of HIV-1 disease were assessed using the CDC classification of HIV-1: class A, asymptomatic or lymphadenopathy; class B: symptomatic, but not AIDS; class C, AIDS. A participant is considered to have had a disease progression if they report a CDC Class C event for the first time, if they report a new CDC Class C event, or if they experience any fatal adverse event during the study. | Baseline (Day 1) up to 31 January 2006 (up to Week 264) | No |
Secondary | Number of Participants Enrolled in Studies APV30001 and APV300002 With the Indicated HIV-associated Conditions | The number of participants with the indicated HIV-associated conditions were assessed, excluding recurrences. | Baseline (Day 1) up to 31 January 2006 (up to Week 264) | No |
Secondary | Number of Participants Enrolled in Study APV30003 and Other Studies With the Indicated HIV-associated Conditions | The number of participants with the indicated HIV-associated conditions were assessed. | Baseline (Day 1) up to 31 January 2006 (up to Week 264) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01425099 -
Drug Interaction Study Between Dolutegravir and Prednisone
|
Phase 1 | |
Completed |
NCT01209117 -
A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
|
Phase 1 | |
Completed |
NCT03231943 -
GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT01195974 -
A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.
|
Phase 1 | |
Completed |
NCT02893488 -
Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet
|
Phase 1 | |
Terminated |
NCT01199731 -
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
|
Phase 2 | |
Completed |
NCT01449929 -
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
|
Phase 3 | |
Active, not recruiting |
NCT02951052 -
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
|
Phase 3 | |
Completed |
NCT01231516 -
A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults
|
Phase 3 | |
Completed |
NCT02273947 -
Food Effect Study With BMS-955176
|
Phase 1 | |
Completed |
NCT00071760 -
Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects
|
Phase 2 | |
Completed |
NCT02539576 -
Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects
|
Phase 1 | |
Completed |
NCT01967771 -
Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT00774735 -
GSK1349572 Drug Interaction Study With Protease Inhibitors
|
Phase 1 | |
Completed |
NCT01077635 -
PENTA Fosamprenavir Study
|
N/A | |
Completed |
NCT00386347 -
A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.
|
Phase 1 | |
Completed |
NCT00945282 -
Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
|
Phase 2 | |
Terminated |
NCT02576119 -
A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects
|
Phase 1 | |
Completed |
NCT02277600 -
A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
|
Phase 1 | |
Completed |
NCT00398125 -
Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults
|
Phase 2 |